Nanoparticle delivery systems in cancer vaccines

Pharm Res. 2011 Feb;28(2):215-36. doi: 10.1007/s11095-010-0241-4. Epub 2010 Aug 19.

Abstract

Therapeutic strategies that involve the manipulation of the host's immune system are gaining momentum in cancer research. Antigen-loaded nanocarriers are capable of being actively taken up by antigen-presenting cells (APCs) and have shown promising potential in cancer immunotherapy by initiating a strong immunostimulatory cascade that results in potent antigen-specific immune responses against the cancer. Such carrier systems offer versatility in that they can simultaneously co-deliver adjuvants with the antigens to enhance APC activation and maturation. Furthermore, modifying the surface properties of these nanocarriers affords active targeting properties to APCs and/or enhanced accumulation in solid tumors. Here, we review some recent advances in these colloidal and particulate nanoscale systems designed for cancer immunotherapy and the potential for these systems to translate into clinical cancer vaccines.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Animals
  • Antigen-Presenting Cells / immunology
  • Antigens, Neoplasm / immunology
  • Cancer Vaccines / immunology*
  • Cancer Vaccines / therapeutic use*
  • Drug Carriers
  • Drug Delivery Systems
  • Humans
  • Immunotherapy / methods*
  • Mice
  • Nanomedicine / methods*
  • Nanoparticles / chemistry*
  • Neoplasms / immunology
  • Neoplasms / therapy

Substances

  • Adjuvants, Immunologic
  • Antigens, Neoplasm
  • Cancer Vaccines
  • Drug Carriers